<4,6-Dioxo-2-thioxo-hexahydro-pyrimidinyliden-(5)>--methan | 90323-03-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: <4,6-Dioxo-2-thioxo-hexahydro-pyrimidinyliden-(5)>--methan
• 英文别名: 5-pyrrol-2-ylmethylene-2-thioxo-dihydro-pyrimidine-4,6-dione；5-(1H-pyrrol-2-ylmethylene)-2-thioxodihydropyrimidine-4,6-dione；5-(1H-pyrrol-2-ylmethylidene)-2-sulfanylidene-1,3-diazinane-4,6-dione
• CAS: 90323-03-8
• 化学式: C₉H₇N₃O₂S
• 分子量: 221.239
• InChiKey: LOHFYOBMBSOJHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  106
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Barbituric acid analogs as therapeutic agents
  申请人：——

  公开号：US20030229108A1

  公开（公告）日：2003-12-11

  This invention pertains to active barbituric acid analogs which inhibit HIF-1 activity (e.g., the interaction between HIF-1&agr; and p300) and thereby inhibit angiogenesis, tumorigensis, and proliferative conditions, such as cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HIF-1 activity, and to inhibit angiogensis, tumorigensis, and proliferative conditions, such as cancer.

  这项发明涉及活性巴比妥酸类似物，其抑制HIF-1活性（例如，HIF-1α与p300之间的相互作用），从而抑制血管生成、肿瘤发生和增生性疾病，如癌症。本发明还涉及包括这些化合物的药物组合物，以及在体外和体内使用这些化合物和组合物来抑制HIF-1活性，以及抑制血管生成、肿瘤发生和增生性疾病，如癌症。
• BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS
  申请人：Novuspharma S.p.A.

  公开号：EP1305026A2

  公开（公告）日：2003-05-02
• [EN] BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS<br/>[FR] ANALOGUES DE L'ACIDE BARBITURIQUE UTILISES COMME AGENTS THERAPEUTIQUES
  申请人：PROLIFIX LTD

  公开号：WO2001093841A2

  公开（公告）日：2001-12-13

  This invention pertains to active barbituric acid analogs which inhibit HIF-1 activity (e.g., the interaction between HIF-1α and p300) and thereby inhibit angiogenesis, tumorigenesis, and proliferative conditions, such as cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HIF-1 activity, and to inhibit angiogenesis, tumorigenesis, and proliferative conditions, such as cancer.